Not an expert in this field, but it seems like they could have pivoted to do a smaller sub-set of blood tests, like the immunoassays. Part of the failure was their insistence that they were going to do ALL blood tests through a finger stick. Once they had raised tens of millions of dollars based on taking the entire market, it was probably too late to de-scope the vision without losing their investors.